Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · IEX Real-Time Price · USD
17.48
-0.05 (-0.29%)
Mar 28, 2024, 4:00 PM EDT - Market closed
Company Description
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally.
It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease.
The company was founded in 2002 and is headquartered in South San Francisco, California.
Gyre Therapeutics, Inc.
Country | United States |
Founded | 2002 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 7 |
CEO | Nassim Usman |
Contact Details
Address: 12770 High Bluff Drive, Suite 150 San Diego, California 92130 United States | |
Phone | (619) 949-3681 |
Website | gyretx.com |
Stock Details
Ticker Symbol | GYRE |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001124105 |
CUSIP Number | 14888D109 |
ISIN Number | US14888D2080 |
Employer ID | 56-2020050 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Nassim Usman Ph.D. | President, Chief Executive Officer and Director |
Seline E. Miller CPA | Senior Vice President of Finance, Interim Chief Financial and Principal Accounting Officer |
Dr. Grant Blouse M.Sc., Ph.D. | Chief Scientific Officer |
Ana Kapor | Senior Director of Investor Relations and Corporate Communications |
Dr. Tom Knudsen D.V.M., Ph.D. | Senior Vice President of Corporate Development |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 28, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Mar 27, 2024 | 10-K | Annual Report |
Mar 26, 2024 | 8-K | Current Report |
Mar 26, 2024 | 8-K | Current Report |
Mar 21, 2024 | 8-K | Current Report |
Mar 15, 2024 | 144 | Filing |
Feb 14, 2024 | 8-K | Current Report |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 24, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Jan 19, 2024 | 8-K/A | [Amend] Current report |